Can a second dose of this radioactive drug beat back prostate cancer again?

NCT ID NCT06866938

Recruiting now Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. It tests whether giving a second course of a radioactive drug called Lu-PSMA can control the cancer again. Participants will receive the drug every six weeks until their disease gets worse or side effects become too severe. The main goal is to see how many men are still alive without their cancer growing after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [177Lu]Lu-PSMA-617 (Pluvicto), a radioactive drug that targets prostate cancer cells
What this could lead to: If successful, this could show that re-treatment with Lu-PSMA is a safe and effective option for men whose prostate cancer has progressed after an initial course of the same therapy.
What could go wrong: This is a small, early-phase (IIb) study with only 58 participants, so results may not apply to all patients. There is also a risk of side effects from the radiation, and the cancer may still progress despite re-treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

CHU de Nancy
NOT_YET_RECRUITING

Vandœuvre-lès-Nancy, 54511, France
Hôpital Louis Pradel, Hospices Civils de Lyon
NOT_YET_RECRUITING

Bron, 69500, France
Institut de cancérologie du Gard
NOT_YET_RECRUITING

Nîmes, 30000, France
Médecine Nucléaire, CHU de Nantes Hôtel-Dieu
NOT_YET_RECRUITING

Nantes, 44000, France
Médecine Nucléaire, Centre Hospitalier de Grenoble Alpes
NOT_YET_RECRUITING

Grenoble, 38043, France
Médecine Nucléaire, Centre Léon Berard
NOT_YET_RECRUITING

Lyon, 69373, France
Médecine Nucléaire, Institut Bergonié
NOT_YET_RECRUITING

Bordeaux, 33000, France
Médecine Nucléaire, Institut Gustave Roussy
NOT_YET_RECRUITING

Villejuif, 94800, France
Médecine Nucléaire, Institut de Cancérologie de Strasbourg
NOT_YET_RECRUITING

Strasbourg, 67200, France
Oncologie Médicale, CHU Brest-Hôpital Morvan
NOT_YET_RECRUITING

Brest, 29200, France
Oncologie Médicale, CHU Saint Etienne
NOT_YET_RECRUITING

Saint-Priest-en-Jarez, 42270, France
Oncologie Médicale, Centre Antoine Lacassagne
NOT_YET_RECRUITING

Nice, 06189, France
Oncologie Médicale, Centre François Baclesse
NOT_YET_RECRUITING

Caen, 14076, France
Oncologie Médicale, Centre Henri Becqueret
NOT_YET_RECRUITING

Rouen, 76038, France
Oncologie Médicale, Centre Hospitalier Lyon Sud, HCL
RECRUITING

Pierre-Bénite, 69310, France
Oncologie Médicale, Centre Jean Perrin
NOT_YET_RECRUITING

Clermont-Ferrand, 63011, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.